FirmaIQ
Org.nr 985 889 635 2014 → 2015 Year-over-year analysis

LYTIX BIOPHARMA ASA: årsregnskap 2015 vs 2014

Grew 136% on revenue, weaker earnings, fresh owner capital

approved 2016-06-16; registry 2016-08-03; journal 2016 772734

Full company analysis · All year comparisons

Summary

What changed

Comparing Årsregnskap 2015 with 2014 for LYTIX BIOPHARMA ASA. Revenue 6.44m NOK → 15.22m NOK (+136.4%). Net result -39.54m NOK → -55.19m NOK. Equity 59.65m NOK → 88.80m NOK.

On the constructive side: revenue rose; equity strengthened; owners injected capital. Pressures included: operating result weakened; net result weakened; cash fell.

Also worth watching: book investments changed. All figures are taken from the published annual accounts for LYTIX BIOPHARMA ASA.

At a glance

Scorecard

Revenue
6.44m NOK 15.22m NOK
+136.4%
Operating result
-40.10m NOK -55.54m NOK
-38.5%
Net result
-39.54m NOK -55.19m NOK
-39.6%
Equity
59.65m NOK 88.80m NOK
+48.9%
Cash
9.08m NOK 8.64m NOK
-4.9%
Total assets
72.13m NOK 108.59m NOK
+50.5%

What improved

  • ↑

    Revenue rose

    Operating income / revenue moved from 6.44m NOK to 15.22m NOK (+136.4% YoY). Calculated

  • ↑

    Equity strengthened

    Book equity 59.65m NOK → 88.80m NOK (equity ratio 82.7% → 81.8%). Calculated

  • ↑

    Owners injected capital

    Paid-in equity rose 59.65m NOK → 88.80m NOK (+29.14m NOK). Reported fact

What deteriorated

  • ↓

    Operating result weakened

    Operating result -40.10m NOK → -55.54m NOK (op. margin -622.6% → -364.8%). Calculated

  • ↓

    Net result weakened

    Net result -39.54m NOK → -55.19m NOK (net margin -613.9% → -362.5%). Calculated

  • ↓

    Cash fell

    Bank deposits 9.08m NOK → 8.64m NOK (-4.9% YoY). Calculated

Things to notice

  • ·

    Book investments changed

    Investment / intangible book value 5 600 NOK → 6.36m NOK. Reported fact